As filed with the Securities and Exchange Commission on February 27, 2018
RegistrationNo. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORMS-8
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
SIERRA ONCOLOGY, INC.
(Exact name of Registrant as specified in its charter)
| | |
| Delaware | | 20-0138994 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification Number) |
c/o 2150 – 885 West Georgia Street
Vancouver, British Columbia, Canada V6C 3E8
(604)558-6536
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2015 Equity Incentive Plan
(Full title of the plan)
Nick Glover
Chief Executive Officer
Sierra Oncology, Inc.
c/o 2150 – 885 West Georgia Street
Vancouver, British Columbia, Canada V6C 3E8
(604)558-6536
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Stephen M. Graham, Esq.
Robert A. Freedman, Esq.
Amanda L. Rose, Esq.
Fenwick & West LLP
1191 Second Avenue
Seattle, WA 98101
(206)389-4510
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule12b-2 of the Exchange Act. (Check one):
| | | | | | |
| Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
| Non-accelerated filer | | ☐ (Do not check if a smaller reporting company) | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
CALCULATION OF REGISTRATION FEE
| | | | | | | | |
|
Title of Each Class of Securities to be Registered | | Amount to be Registered (1) | | Proposed Maximum Offering Price Per Unit | | Proposed Maximum Aggregate Offering Price | | Amount of Registration Fee |
Common Stock, $0.001 par value | | | | | | | | |
— To be issued under the 2015 Equity Incentive Plan | | 2,095,808(2) | | $2.98(3) | | $6,245,508 | | $777.57 |
|
|
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Registrant’s 2015 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock. |
| (2) | Represents additional shares of common stock reserved for issuance under the Registrant’s 2015 Equity Incentive Plan as of January 1, 2018. |
| (3) | Calculated solely for the purposes of this offering under Rules 457(c) and (h) of the Securities Act on the basis of the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on February 23, 2018. |
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of FormS-8, Sierra Oncology, Inc. (the “Registrant”) is filing this Registration Statement with the SEC to register 2,095,808 additional shares of common stock under the Registrant’s 2015 Equity Incentive Plan (“EIP”), pursuant to the provisions of the EIP providing for an automatic increase in the number of shares reserved for issuance under the EIP on January 1, 2018.
This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on FormS-8 filed with the Securities and Exchange Commission (the “Commission”) on July 16, 2015 (RegistrationNo. 333-205693). In accordance with the instructional note to Part I of FormS-8 as promulgated by the Commission, the information specified by Part I of FormS-8 has been omitted from this Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 3. | Incorporation of Documents by Reference. |
The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:
| | (a) | the Registrant’s Annual Report on Form10-K for the year ended December 31, 2017 filed with the Commission on February 27, 2017 pursuant to Section 13 of the Exchange Act; |
| | (b) | all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form10-K referred to in (a) above; and |
| | (b) | the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form8-A (FileNo. 001- 37490) filed on July 8, 2015 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description. |
All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.
The following exhibits filed or furnished as part of this Registration Statement on FormS-8 are set forth below. Where so indicated by footnote, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on FormS-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, Province of British Columbia, on this 27th day of February 2018.
| | |
| SIERRA ONCOLOGY, INC. |
| |
| By: | | /s/ Nick Glover |
| | Nick Glover |
| | President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Nick Glover and Sukhi Jagpal, and each of them, as his or her true and lawfulattorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on FormS-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto saidattorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that saidattorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
| | | | |
Name | | Title | | Date |
| | |
/s/ Nick Glover Nick Glover | | President, Chief Executive Officer and Director (Principal Executive Officer) | | February 27, 2018 |
| | |
/s/ Sukhi Jagpal Sukhi Jagpal | | Chief Financial Officer (Principal Financial and Accounting Officer) | | February 27, 2018 |
| | |
/s/ Donald Parfet Donald Parfet | | Chairman of the Board | | February 27, 2018 |
| | |
/s/ Andrew Allen Andrew Allen | | Director | | February 27, 2018 |
| | |
/s/ Jeffrey H. Cooper Jeffrey H. Cooper | | Director | | February 27, 2018 |
| | |
/s/ Daniel Estes Daniel Estes | | Director | | February 27, 2018 |
| | |
/s/ Tran Nguyen Tran Nguyen | | Director | | February 27, 2018 |
| | |
/s/ Nicole Onetto Nicole Onetto | | Director | | February 27, 2018 |
| | |
/s/ Robert Pelzer Robert Pelzer | | Director | | February 27, 2018 |
